Insider Purchases: Inside the Buy
Tag: Funanc1alInsiders
Does Align Technology’s Recovery Plan Have Teeth? The CEO Thinks So.
Align Technology insiders are smiling—because they’re buying. With a CEO purchase nearing $1M and Wall Street holding more shares than exist, ALGN may be regaining its shine. But should you sink your teeth into it now?
EPD: Enterprise Products Partners Is Boring—But It Pays to Be Boring
Enterprise Products Partners (EPD) might not make headlines, but it makes money. With insiders buying big, a solid 7% dividend, and decades of steady growth, this is one midstream stock that flows cash — not drama.
Insiders Bought "MicroStrategy" Shares at $90. You’re Paying $394.66. Should You?
MSTR insiders are buying, but not the stock you think. They bought STRC at $90 — while MSTR trades near $400. What gives? We break down the numbers, the Bitcoin twist, and what might be worth nibbling on.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Simmons Bank: Insider Buys, 116 Years of Dividends, and a Footlong Public Offering
Simmons Bank has paid dividends for over a century—and insiders just went on a buying spree. 📉 Stock’s dipped, 🔍 valuation isn’t screaming cheap, but with improving net income and institutional support, SFNC might be worth a second look. If not exciting, at least it’s… dependable?
Helen of Troy (HELE) — Insider Buys, CFOs Turned CEOs, and a Falling Knife You Might Want to Catch (Carefully)
The CEO and CFO of Helen of Troy just bought shares as the stock plunges 90%. Are we looking at a tragic tale, or a comeback for the ages? We dig into the numbers, leadership shuffle, and Wall Street signals—with humor and historical flair.
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Will Profits From Marriott Vacations (VAC) Help You Unwind?
Insiders are buying, institutions are lounging, and dividends are flowing. Marriott Vacations Worldwide (VAC) might be your next profitable getaway — with a 3.9% yield and room to grow. But are there risks under the palm trees?
Oxford Industries’s Tommy Bahama and Lilly Pulitzer Rock: Should You Emulate Insiders and Buy More Than the Brands?
Oxford Industries owns some of the most recognizable lifestyle brands—Tommy Bahama, Lilly Pulitzer, and Johnny Was. Sales are soft, but margins hold, insiders are buying, and the dividend is sweet. Time to sip a piña colada—and check the stock price?